A slide from a presentation about the history of opioid REMS. It has a blue background and white text. The slide is divided into three sections. The first section is titled "FDA Amendments Act gave FDA authority to require a REMS". It states that the FDA amendments act gave FDA approval to require the REMS in 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 and 2021. The second section is labeled "Two more opioid REMs approved for morphine sulfate/nucleotide hydrochloride (embed) and fentanyl buccal soluble film (Oxycontin)". The third section is labelled "Three tire REMS approved in 2011: fentanyl sublingual tablet (astral) fentanyl nasal spray (agenda) in December 2011 Fentanyl (Fentanyl) and oral transducer (Citric acid)". At the bottom of the slide there is a title that reads "History of Opioid REMS" and a brief description of the program.
Description 
Type
Category
-
Date
2017
Collection
We encourage you to view the image in the context of its source document(s) and cite the source(s) when using these images. However, to cite just this image alone, click the “Cite This Image” button and then paste the copied text.
![An advertisement for Nucynta ER with sections for "Discontinuation Rates Due to Adverse Events" and "Incidence of Opioid Withdrawal Symptoms". There is also a bar graph with the title "Incidence of treatment-emergent adverse events leading to discontinuation reported by [greater than or equal-to] 2% of patients". The background is white and red with text in red black and white.<br /><br />On the right side there is "Selected Important Safety Information". The logo of logo of Nucynta ER is at the bottom.](https://oida-resources-images.azureedge.net/public/full/38ba2066-6f55-47b4-9093-78b9be045673.jpg)
